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We report two families with Brunner syndrome living in one state of
Australia. The first family had a predicted protein-truncating variant of
monoamine oxidase A (MAOA) (p.S251KfsX2). Affected males had mild
intellectual disability (ID), obsessive behaviour, limited friendships and were
introverted and placid during clinical interview. The family disclosed
episodic explosive aggression after a diagnosis was made. The second family
had a missense variant in MAOA (p.R45W). Affected males had
borderline-mild ID, attention deficit disorder and limited friendships. One
had a history of explosive aggression in childhood and episodic symptoms of
flushing, headaches and diarrhoea. Their carrier mother had normal
intelligence but similar episodic symptoms. Characteristic biochemical
abnormalities included high serum serotonin and urinary metanephrines and
low urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid
(VMA). Symptomatic individuals in the second family had particularly high
serotonin levels, and treatment with a serotonin reuptake inhibitor and
dietary modification resulted in reversal of biochemical abnormalities,
reduction of ‘serotonergic’ symptoms and behavioural improvement.
Brunner syndrome should be considered as a cause of mild ID with
paroxysmal behavioural symptoms. It can be screened for with serum/urine
metanephrine and serotonin measurement. Cautious treatment with a
serotonin reuptake inhibitor, dietary modifications and avoidance of
medications contraindicated in patients on monoamine oxidase inhibitors
can improve symptoms.
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New insights into Brunner syndrome
Brunner syndrome (OMIM 300615) was first described
in 1993 in a large Dutch kindred. Linkage to Xp11-21
was obtained, and biochemical evidence of monoamine
oxidase A (MAOA) deficiency and a subsequent
protein-truncating variant in the MAOA gene was iden-
tified (1, 2). The affected males had non-syndromic
borderline-mild intellectual disability (ID) with
stress-induced aggressive outbursts. Aberrant sexual
behaviour and episodic night terrors were characteristic.
Subsequently, there has been debate regarding possible
influences of polymorphisms in the MAOA gene and
behavioural dysinhibition, especially in the context of
childhood stress exposure (3, 4). Brunner syndrome
because of pathogenic variants in the MAOA gene has
been infrequently observed despite active screening of
X-chromosome-linked intellectual disability (XLID)
cohorts (5). We are aware of two further reports: one
family, genetically characterised herein, and previously
only identified biochemically (6) and another recent case
report (7) of males with variable ID/autism spectrum
disorder, aggressive behaviour, a missense variant in
MAOA and abnormal urinary monoamines.
There are two genes coding for two specific iso-
forms ofmonoamine oxidase (MAO),MAOA andMAOB,
located at Xp11.2. The MAO enzymes have key roles
in oxidative deamination of the neurotransmitters sero-
tonin, dopamine, adrenaline and noradrenaline, as well as
metabolising minor amines including tyramine. MAOA
is more biologically active and loss of function ofMAOB
alone because of a partial gene deletion has not been
associated with biochemical or clinical sequelae (8).
Materials and methods
Clinical description of the families
Family H
The pedigree (Fig. 1) consisted of two non-dysmorphic
well-grown brothers III:1, 59 years, and III:4, 52 years,
with mild ID and essential tremor (clinical details
Table 1). They had an affected maternal uncle (II:3)
who died at 60 years of age following a motor vehicle
accident (unavailable for genetic testing). Notably,
behaviour problems were not reported on initial assess-
ment with both males appearing very passive during
clinical interview. Direct questioning later revealed
III:1’s history of impulsivity, school expulsions and vio-
lent episodes involving property damage and aggression
towards family members. III:4 had a history of explosive
temper, affecting his ability to maintain employment, as
well as limited interests and obsessive behaviour with
significant hoarding. III:4 would occasionally become
infatuated with female acquaintances. Both males had
difficulties with sleep onset but no history of night
terrors. Neither affected male had stereotypical hand
movements although III:4, repetitively, combs his hair
and both have infrequent involuntary body twitches and
essential tremor. No anti-depressant or psychotropic
medication had been prescribed. No specific seroton-
ergic symptoms or worsening of behaviour with high
tyramine foods or medication were noted.
Family R
This family was previously reported by Cheung and
Earl (6). An adult female patient of normal intelli-
gence presented with paroxysmal episodes of flushing,
diarrhoea, headache and palpitations. She was initially
suspected to have carcinoid syndrome, but urinary
5-hydroxyindoleacetic acid levels, abdominal and chest
computerized tomography (CT) scans, and somato-
statin receptor scan were normal. Further investigation
identified raised serum and platelet serotonin and low
levels of serotonin metabolites compatible with MAOA
deficiency. We recently reviewed this family (Table 1).
III:4 has two adult sons aged 33 (IV:5) and 31 (IV:6)
years, both of whom have borderline-mild ID and
attention-deficit hyperactivity disorder (ADHD). IV:5
had a history of impulsive behaviour and aggressive
outbursts in childhood initially treated as epileptic
without any noticeable benefit from medication. From
adolescence, IV:5 had symptoms of episodic flush-
ing, diarrhoea and headache. IV:6 had difficulties
sustaining friendships and obsessive symptoms. IV:5
had recurrent severe nightmares from childhood into
adolescence. Neither affected male had persistent abnor-
mal sexual behaviour although neither have had a
sustained relationship with a female partner. Neither
affected male have stereotypical hand movements;
both have an essential tremor (as does their unaf-
fected father), and IV:5 has occasional finger and leg
‘twitches’.
All affected individuals in Family R notice an exac-
erbation of serotonergic symptoms when they consume
food and drink high in tyramine, especially beer, cheese
and ‘vegemite’ (yeast extract). These foods were a
trigger for the aggressive outbursts for IV:5. Patients
III:4, IV:5 and IV:6 were cautiously commenced on
50mg/day of sertraline, a selective serotonin reuptake
inhibitor (SSRI). The dose ofmedicationwas very slowly
increased under hospital admission supervision. There
were initial exacerbation of serotonergic symptoms, but
then III:4 and IV:5 (the more severely affected individu-
als) reported reduction in the frequency of headaches and
flushing, severity of diarrhoea and improvement inmood.
A reduction in aggressive outbursts for IV:5 was noted
by his family. III:4 reported similar beneficial effects on
venlafaxine (37.5mg/day increased to 75mg/day). Com-
plete normalisation of biochemistry was demonstrated
on treatment with sertraline (6); however, even on
treatment, affected individuals report re-emergence
of milder serotonergic symptoms with dietary
indiscretions.
III:5 was recently briefly trialled off sertraline 10 years
after treatment was commenced, on request of his fam-
ily. Repeat bioamine profiling (on and off SSRI medica-
tion) demonstrated a normalisation of serum serotonin
and normetanephrine/metanephrine on medication and
re-elevation off medication (Fig. 2 and Table S1, Sup-
porting Information). Off medication, he had frequent
episodes where he was flushed, diaphoretic, disorien-



















New insights into Brunner syndrome
X-exome sequencing
Family H
The proband from this family, III:4, was investigated by




DNA extracted from whole-blood (QIAamp DNA blood
maxi kit; Qiagen, Limburg, The Netherlands) was part
of a large X-chromosome exome sequencing study (9).
Only one affected individual was sequenced (Illumina
GAIIx; Max Planck Institute for Molecular Genetics,
Berlin, Germany). Confirmation of variants by Sanger
sequencing was carried out using standard methods.
Family R
DNAwas extracted from lymphocytes, and DNA Sanger
sequencing of the MAOA gene (NM_000240.2) was
performed using standard methodology (Laboratorium
Genoomdiagnostiek, UMS St Radboud, Nijmegen, The
Netherlands).
Bioamine assays
Plasma noradrenaline and adrenaline levels, serum
serotonin levels, and urine levels of catecholamines,
metanephrine, normetanephrine and 5HIAA levels were
quantitated by high-performance liquid chromatogra-
phy (HPLC) with electrochemical detection. Plasma
metanephrine and normetanephrine levels were quan-




A single base pair insertion in exon 5 of the MAOA
gene was identified. This DNA variant is predicted to
result in a truncated MAOA protein, c.749-750insT;
p.S251KfsX2 (using NM_000240) (Fig. 1d).The variant
was present in both males, and their mother was assumed
to be an obligate carrier.
The deleterious effect of the variant was confirmed by
profiling the bioamine levels in blood and urine in this
family (Fig. 2 and Table S1). These biochemical results
are similar to those previously reported by patients with
Brunner syndrome (1, 6, 7; Fig. 2 and Table S1).
Family R
Sequencing revealed a rare novel missense vari-
ant c.133C>T (p.Arg45Trp) in MAOA (transcript
ENSP00000340684) (Fig. 1d). This variant is not present
in the ExAC dataset [Exome Aggregation Consor-
tium, Cambridge, MA (http://exac.broadinstitute.org),
accessed December 2014], affects an evolutionarily
conserved residue (down to Xenopus) (Fig. 1f) and is
predicted to have a functional impact based on in silico
prediction software including provean [Protein Varia-
tion Effect Analyser (http://provean.jcvi.org/index.php)]
(predicted pathogenic – score −6.7) and Mutation-
taster [Mutation Taster (http://mutationtaster.org/)]
(disease causing). The variant introduces a larger and
more hydrophilic amino acid in the oxidase [flavin
adenine dinucleotide (FAD) binding] domain of the
protein (Fig. 1g), predicted to impact on substrate
binding and protein folding (Fig. 1e). The variant was
present in both affected males, and their symptomatic
mother; but not present in the maternal grandmother.
The maternal grandfather was unavailable for testing.
All variants have been submitted to Clinvar [ClinVar
(www.ncbi.nlm.nih.gov/clinvar/].
Bioamine levels for affected family members are sum-
marised in Fig. 2 (detailed information in Table S1).
MAOA substrates serotonin and normetanephrine were
elevated, and bioamine metabolites were in the low nor-
mal range. The effect on serotonin metabolism was more
marked than that on catecholamine metabolism.
Discussion
Brunner syndrome has been an uncommonly diagnosed
cause of XLID with only two new cases reported in the
last 20 years (6, 7). The identification of at least two cases
in the Australian state of New South Wales suggests
that the scarcity of cases may represent problems with
ascertainment, rather than rarity of the phenotype. In
both of the families that we report, the degree of develop-
mental delay in affected males was mild and semi-open
Fig. 1. Pedigrees of the two families and characterisation of MAOA variants. (a) Pedigree for Family H showing Sanger results of MAOA sequencing.
Primers flankingMAOA exon 7 were used to amplify and sequence gDNA, F – 5′-TGG CCT GTG ACT TTC TGG A-3′ and R – 5′-GCA GGC GTG
AAA AAT CAT CT-3′. Arrow indicates nucleotide variant site (Hg19: ChrX: 43590591–43590592, ins1bp, p.S251KfsX2). (b) Pedigree for Family R.
(c) Position of MAOA gene on X-chromosome (integrative genomics viewer, IGV); (d) location of functional domains of MAOA protein and position
of variants for Family R and H and those described by Brunner et al. (2) and Piton et al. (7). FAD (blue boxes)=flavin adenine dinucleotide binding
domains: residues 13–88, 220–294, and 400–462; SBD (red boxes)= substrate-binding domain: residues 89–219 and 295–399; CTM (green box)
C-terminal membrane region: residues 463–506. The active site cavity-shaping loop (residues 210–216) is depicted as black box. The missense variant
for Family R lies within a FAD-binding domain, as does the missense variant for the family described by Piton et al. (7). (e) Close-up of the predicted
structural effect of Family R variant (R45W) – the missense variant is predicted to introduce a larger, more hydrophobic residue that will cause an
ionic interaction within the protein to be lost. The protein is coloured grey, the side chains of both the wild-type and the mutant residue are shown and
coloured green and red, respectively (16); (f) conservation of residue R at position 45 (highly conserved down to Xenopus tropicalis) (15) (g) Reprinted





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2. Changes in bioaminemetabolism in patients withmonoamine oxidase A (MAOA) deficiency. (a) Serotoninmetabolism pathwaywith changes in
metabolites detected in patients affected by MAOA deficiency. MAOA substrate serotonin (red) elevated and breakdown product 5-hydroxyindoleacetic
acid (5-HIAA) (blue) decreased or unchanged. (b) Catecholamine metabolism pathway with changes in metabolites detected in patients affected by
MAOA deficiency. MAOA substrates normetanephrine and metanephrine (red) elevated and breakdown products vanillylmandelic acid (VMA) and
homovanillic acid (HVA) (blue) decreased or unchanged. (c) Comparison of bioamine metabolite results for affected patients in Family H, R, Brunner
et al. (1) and Piton et al. (7) families. Elevations in MAOA substrates normetanephrine, metanephrine and serotonin levels are the most consistent
biochemical signature for MAOA deficiency. These metabolite levels were completely normalised in affected individuals from Family R treated with a
selective serotonin reuptake inhibitor (SSRI) (column 4). Absolute values are listed in Table S1. NT, not tested.
employment, and independent living was possible. It
is conceivable that the cohorts of patients that have
previously been screened for Brunner syndrome had
more significant cognitive disability. There has also been
debate and potential misinterpretation of the behavioural
characteristics of affected males (10, 11): episodic
impulsive behaviour leading at times to physical aggres-
sion seems to be the most important behavioural clue.
Affected males also had autistic features, including lack
of friendships, difficulties interpreting female relation-
ships, narrow interests and obsessional collecting. Sim-
ilar characteristics were reported in the family described
by Piton (7). Parasomnias, including night terrors, and
subtle neurological symptoms of tremor, stereotypical
handmovements or occasional body twitches also appear
to be characteristic. Abnormal bioamines are an effec-
tive way to follow up the significance of any detected
variants in MAOA (e.g. from genomic screening).
Specific questioning regarding ‘serotonergic syn-
drome’ symptoms (episodic flushing, headaches and dia-
rrhoea) and the exacerbation of physical and behavioural
symptoms with high tyramine-containing foods and
drinks, such as cheese and yeast extract, may also
be diagnostically helpful. These symptoms are not
mentioned in the case reports of Brunner and Piton, but
may not have been specifically elicited. Serotonergic
symptoms may not be universal for Brunner syndrome:
there may be genotype–phenotype correlation. They
were not present in affected members of Family H, who
had a loss of function variant, but were prominent in
Family Rwho had amissense variant. The affectedmem-
bers of Family R had particularly high serotonin levels
off medication. It is possible that the conformational
change of the oxidase-binding site in affected members
of Family R may selectively affect serotonin metabolism
more than other bioamines (Fig. 2). TheMAOAmissense
variant Y444F has such a specific effect (12). Additional
functional work and evaluation of further clinical cases
is required to investigate this further.
We suggest that behavioural issues in individuals
affected by Brunner syndrome are related to elevated
serotonin, although the mechanism is incompletely
understood at the synaptic level. Elevated platelet sero-
tonin has been associated with autism spectrum disorder
(13) and a low efficiency promoter region polymorphism
within the MAOA gene associated with autism severity
and aggression (14). An MAOA-deficient mouse model
suggests serotonin elevation may result in an increase
in the frequency and intensity of physical aggression
between male mice (15).
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The amelioration of physical and behavioural symp-
toms with SSRI/SNRI (seratonin-norepinephrine reup-
take inhibitor) medication in Family R is difficult to
explain comprehensively. This appears paradoxical, as
the anti-depressant/anti-anxiolytic effect of this medi-
cation is postulated to be because of an increase of
monoamines at brain synapses, and these medications
are contraindicated in patients taking a monoamine oxi-
dase inhibitor due to the risk of precipitating sero-
tonergic syndrome. However, there is supportive ani-
mal model data that administration of the SSRI flu-
oxetine reduces aggressive behaviour and perseverative
responses in MAOA knockout mice and improves social
deficits and perseverative responses in mice with a hypo-
morphicMAOA variant (16). The authors were surprised
by this treatment effect as they had anticipated that the
SSRI would worsen symptoms.
Earl and Cheung (6), who originally recommended
a therapeutic trial of SSRI in Family R, postulated
that symptoms related to serotonergic excess would be
reduced over time because of reduction of peripheral
serotonin. Blood serotonin levels fall in individuals
treated with SSRI’s due to inhibition of platelet sero-
tonin transporters, platelets being the major storage
site of serotonin in the blood (17). The exact effect
of SSRI/SNRI medication acutely and chronically in
different brain regions even in individuals with normal
MAOA function is far from understood (18), and it
is difficult to say whether improvements in mood and
behaviour in treated members of Family R were purely
because of relief of physical symptoms or an additional
central effect.
Cautious treatment with an SSRI may be useful in
other families with Brunner syndrome, particularly in
individuals with high serotonin levels and debilitating
‘serotonergic symptoms’. Such treatment trials carry
the risk of precipitating life-threatening serotonergic
syndrome as patients with Brunner syndrome likely have
increased stores of serotonin because of loss of MAOA
function. We would recommend that an SSRI/SNRI
be started at the lowest possible dose with very slow
escalation and close cardiovascular and neurological
monitoring over at least a 2-week hospital admission.
The potential of tyramine-containing foods and cer-
tain medication (those contraindicated in patients on
a monoamine oxidase inhibitor) to precipitate poten-
tially life-threatening serotonergic symptoms points to
the additional medical importance of diagnosing Brunner
syndrome. We would advise individuals diagnosed with
Brunner syndrome to be referred to a dietician, avoid
medication contraindicated in patients on monoamine
oxidase inhibitors unless under strict medical supervi-
sion and be issued with ‘Medic-Alert’ bracelets.
Supporting Information
Additional supporting information may be found in the online
version of this article at the publisher’s web-site.
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